Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX

Citigroup Inc. grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 95.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 152,580 shares of the company’s stock after buying an additional 74,629 shares during the quarter. Citigroup Inc. owned 0.24% of Protagonist Therapeutics worth $10,136,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Bessemer Group Inc. raised its position in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after purchasing an additional 318 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of Protagonist Therapeutics in the 3rd quarter valued at $29,000. CWM LLC raised its holdings in shares of Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after buying an additional 407 shares in the last quarter. Abich Financial Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics during the 3rd quarter worth $62,000. Finally, Osaic Holdings Inc. lifted its position in shares of Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after buying an additional 525 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised its FY2026 EPS view to $4.18 (from $3.40) and sharply boosted the Q3 2026 estimate to $3.60 (from $0.05), signaling stronger near‑term profit expectations that likely support today’s upside. MarketBeat PTGX
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $117 price objective — a positive endorsement that can attract momentum buyers and institutional attention. MarketBeat PTGX
• Neutral Sentiment: Modest near‑term estimate tweaks: Q1 2026 EPS was nudged from ($0.71) to ($0.70) and Q2 2026 was trimmed slightly to $1.98 (from $2.03) — small adjustments that are unlikely to move fundamentals materially on their own. MarketBeat PTGX
• Neutral Sentiment: Benzinga published an analyst roundup summarizing expert views on Protagonist, helpful for context but not a single‑catalyst item. A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts
• Negative Sentiment: HC Wainwright cut several multi‑year estimates sharply: FY2027 to ($2.06), FY2028 to ($2.08) (from +$0.40), FY2029 to $0.12 (from $4.56) and FY2030 to $1.22 (from $5.40). These downgrades introduce longer‑term earnings uncertainty and could limit sustained upside absent confirming clinical/commercial catalysts. MarketBeat PTGX
• Negative Sentiment: HC Wainwright also revised Q4 2026 from a previously higher figure to ($0.71), a notable near‑term miss relative to their prior view that may reflect timing or one‑off items in the model. MarketBeat PTGX

Analyst Ratings Changes

PTGX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their target price on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Citizens Jmp raised their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research note on Thursday. Jefferies Financial Group lifted their price target on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Barclays increased their price objective on shares of Protagonist Therapeutics from $108.00 to $113.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Weiss Ratings lowered shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $99.31.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $92.08 on Friday. Protagonist Therapeutics, Inc. has a 52 week low of $35.97 and a 52 week high of $96.54. The firm’s fifty day moving average is $84.24 and its 200-day moving average is $77.02. The firm has a market cap of $5.88 billion, a P/E ratio of -44.92 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The business had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.50%. As a group, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Insider Activity

In related news, Director William D. Waddill sold 20,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $654,796. This trade represents a 71.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total transaction of $410,000.00. Following the completion of the sale, the insider directly owned 84,115 shares in the company, valued at $6,897,430. This trade represents a 5.61% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 203,167 shares of company stock worth $16,889,199. Company insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.